NovoCure (NASDAQ:NVCR – Get Free Report) issued its earnings results on Thursday. The medical equipment provider reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11), FiscalAI reports. NovoCure had a negative return on equity of 39.11% and a negative net margin of 20.79%.The firm had revenue of $174.06 million for the quarter, compared to analysts’ expectations of $167.77 million. During the same period last year, the firm earned ($0.31) earnings per share. NovoCure’s revenue for the quarter was up 12.3% on a year-over-year basis.
Here are the key takeaways from NovoCure’s conference call:
- Strong commercial and financial start to 2026 — net revenue was $174 million (+12% YoY) with double‑digit active patient growth, and the company raised full‑year revenue guidance to $690M–$710M and updated Adjusted EBITDA guidance to -$15M to breakeven.
- Optune PAX FDA approval and U.S. launch showed early traction — in ~7 weeks the company certified 868 HCPs, received 169 prescriptions, completed 90 patient starts (83 patients on therapy at quarter end), and secured first major payer coverage for >30M lives.
- Clinical momentum in pancreatic cancer — PANOVA‑4 met its primary endpoint (DCR 74% vs 48% historical) and PANOVA‑3 results plus preclinical data (including potential synergy with KRAS inhibitors) support further combo development and metastatic program exploration.
- Q1 GAAP loss widened due to a one‑time charge — net loss was $71M (vs $34M a year ago) largely from a $43M share‑based compensation charge tied to Optune PAX approval; excluding that charge, net loss was $28M, with cash and investments of $432M at quarter end.
NovoCure Trading Up 7.3%
Shares of NovoCure stock traded up $1.11 on Friday, reaching $16.32. The company had a trading volume of 366,263 shares, compared to its average volume of 1,776,256. The firm’s 50 day moving average price is $12.11 and its two-hundred day moving average price is $12.45. The firm has a market cap of $1.89 billion, a PE ratio of -13.51 and a beta of 0.82. NovoCure has a 52-week low of $9.82 and a 52-week high of $20.06. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.71 and a current ratio of 2.90.
Wall Street Analyst Weigh In
View Our Latest Report on NVCR
More NovoCure News
Here are the key news stories impacting NovoCure this week:
- Positive Sentiment: Management raised its FY2026 sales outlook to a $690M–$710M range, slightly above consensus and signaling confidence in demand — this guidance boost was a primary catalyst for the rally. Novocure jumps after raising FY26 sales outlook, Q1 revenue beat
- Positive Sentiment: Q1 revenue beat estimates: revenue of $174.06M vs. analysts’ ~$167.8M, up ~12.3% year-over-year — the top-line beat underpins the stronger guidance and investor enthusiasm. NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
- Positive Sentiment: Market reaction was strong (large intraday gain reported by several outlets) as investors prioritized revenue/guidance over the EPS miss. Why NovoCure Limited’s (NVCR) Stock Is Up 19.53%
- Neutral Sentiment: Full Q1 earnings call transcript and investor slide deck are available for detail on drivers (regional trends, product uptake, and margin outlook) — useful for assessing sustainability of the revenue trend. NovoCure Limited (NVCR) Q1 2026 Earnings Call Transcript
- Negative Sentiment: Earnings missed: EPS was ($0.62) vs. consensus (~$-0.51) and widened from ($0.31) a year ago — the larger loss tempers the positive reaction and highlights ongoing profitability challenges. NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates
- Negative Sentiment: Profitability metrics remain weak (negative net margin and ROE), and consensus still models a negative FY EPS — investors should weigh revenue momentum against continued losses. NovoCure: Q1 Earnings Snapshot
Insiders Place Their Bets
In other news, CFO Christoph Brackmann sold 6,412 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total value of $85,343.72. Following the sale, the chief financial officer directly owned 182,842 shares of the company’s stock, valued at approximately $2,433,627.02. The trade was a 3.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Mukund Paravasthu sold 43,246 shares of the business’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $13.77, for a total transaction of $595,497.42. Following the completion of the sale, the chief operating officer directly owned 72,832 shares in the company, valued at $1,002,896.64. This trade represents a 37.26% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 140,041 shares of company stock worth $1,860,116. Insiders own 5.52% of the company’s stock.
Institutional Investors Weigh In On NovoCure
Large investors have recently added to or reduced their stakes in the business. Polymer Capital Management US LLC purchased a new stake in NovoCure during the 4th quarter worth approximately $176,000. Captrust Financial Advisors purchased a new stake in NovoCure during the 4th quarter worth approximately $138,000. Royal Bank of Canada increased its stake in NovoCure by 14.9% during the 4th quarter. Royal Bank of Canada now owns 12,830 shares of the medical equipment provider’s stock worth $166,000 after buying an additional 1,667 shares during the period. WINTON GROUP Ltd purchased a new stake in NovoCure during the 4th quarter worth approximately $166,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in NovoCure during the 3rd quarter worth approximately $140,000. 84.61% of the stock is owned by hedge funds and other institutional investors.
About NovoCure
NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.
Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.
See Also
Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.
